Psycheceutical Bioscience, Inc (OTCPK: BWVI) is a cutting-edge biotech startup that developed a topical drug delivery system called NeuroDirect, a system that can be used to deliver psychedelic drugs directly to the brain, avoiding the traditional “high” and side effects.

The company is currently conducting trials in Australia for the treatment of PTSD and complex regional pain syndrome. Earlier this month, Psycheceutical announced the completion of dosing the first cohort of subjects in a Phase I clinical trial of its topical ketamine formulation for PTSD.

So Far, So Good

If successful, NeuroDirect could have applications for a wide range of neuro-related conditions, including Parkinson’s, drug addiction and traumatic brain injury.

Backed by Shark Tank investor Kevin Harrington and led by Mike Zapolin, AKA Zappy, a former Wall Street VP, chief visionary officer and advisor to Psycheceutical.

Zappolin, who spoke at the April Benzinga Psychedelics Capital Conference in Miami explained that the company has also received a number of patents for topical back-of-the-neck drug delivery. This approach could …

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.